ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1033

Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

Ye Cao1, Stephen Alves 2, Corine Sinnette 3, Cameron Speyer 3, Gregory Keras 1, Yujie Qu 2, Joshua Keegan 4, James Lederer 4, Deepak Rao 3 and Karen Costenbader 3, 1Brigham and Women's Hospital, Boston, 2Merck, boston, 3Brigham and Women's Hospital, Boston, MA, 4BWH, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cells and Disease Activity, CD T cells, CyTOF, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may reveal pathways that are fundamental drivers of the autoimmune response in SLE. Mass cytometry provides a powerful method to broadly assess immune cell phenotypes in samples from patients and may reveal immune cell subsets that are most prominently altered in SLE patients compared to controls.

Methods: We used two 39-marker mass cytometry panels (a T cell panel and B cell panel) to evaluate CD4+ T cells and B cells in cryopreserved peripheral blood mononuclear cells from patients with new-onset SLE (diagnosis within 6 months, n=10), compared to patients with established SLE (n=15), and non-inflammatory controls (n=14). All SLE patients met the 1997 ACR classification criteria for SLE. New-onset SLE patients were naïve to immunosuppressive therapy; hydroxychloroquine and prednisone ≤ 10mg/day were permitted. Established SLE patients were on a range of treatments. We used FlowSOM to define and quantify metaclusters of memory CD4+ T cells and B cells based on their 39-parameter characterization. We used Student’s t-test to identify significantly altered metaclusters in SLE patients (p< 0.05). Expanded cell populations were confirmed by biaxial gating.

Results: We identified 15 metaclusters (i.e. cell populations) of memory CD4+ T cells by FlowSOM. Of these, 4 T cell metaclusters were significantly increased in new-onset SLE patients compared to healthy controls (Figure 1). Three of these 4 metaclusters were also increased in established SLE patients. Analysis of marker expression on these cell populations revealed that all 4 populations displayed high expression of PD-1 and ICOS. One of the populations also expressed CXCR5, consistent T follicular helper (Tfh) cells, while the other 3 lacked CXCR5, consistent with T peripheral helper (Tph) cells, a CXCR5- B cell-helper T cell population initially identified in RA joints. Biaxial gating confirmed a significant expansion of both Tph cells (2.0-fold, p=0.034) and Tfh cells (2.4-fold, p=0.001) in new-onset SLE patients. In the analysis of B cells by FlowSOM, we identified 3/15 B cell metaclusters significantly expanded in new-onset SLE patients (Figure 2). Cells in all 3 of these metaclusters showed a CD11c+ Tbet+ CD21- phenotype consistent with age-associated B cells (ABCs). The 3 metaclusters were distinguished by expression of distinct immunoglobulin isotypes representing IgM+, IgG+, and IgA+ ABCs. Across all patient groups, the frequency of Tph cells was positively correlated with the frequency of ABCs (r=0.34,p=0.036), including both IgG+ and IgM+ ABCs, and with the frequency of Tfh cells (r=0.44,p=0.005). Tph cells, but not Tfh cells, also showed a negative association with serum complement C3 levels (r=-0.51,p=0.017), a marker of disease activity in SLE.

Conclusion: Broad immunophenotyping analyses highlight marked expansion of Tph cells, Tfh cells, and ABCs are prominent features of the immune dysregulation in patients with new-onset, immunosuppressant-naïve SLE. These cells may be involved in the early phases of the pathologic autoimmune response in SLE.


ACR_Figure1

Figure1. Expanded PD-1hi CXCR5- Tph cells and PD-1hi CXCR5+ Tfh cells in blood of new-onset SLE patients.
A. FlowSOM analysis of CD45RO+ CD4+ T cells shows an increased abundance of T cell metaclusters 4,5,6,11. Metaclusters 4,6,11 are PD-1hi CXCR5- cells. Metacluster 5 is PD-1hi CXCR5+ cells. *Student’s t-test p<0.05.
B. Quantification of Tph cells -PD-1hi CXCR5– and Tfh cells -PD-1hi CXCR5+- cells by biaxial gating. * p<0.05, ** p<0.01, *** p<0.001 by Mann-Whitney U test.


ACR_Figure2

Figure2. Expanded CD11c+ ABCs in the blood of new-onset and established SLE patients.
A. FlowSOM analysis of total B cells shows an increased abundance of B cell metaclusters 3,7 and 9. Metacluster 3 is IgG+ ABCs. Metacluster 7 is IgA+ ABCs. Metacluster 9 is IgM+ ABCs. *Student’s t-test p<0.05.
B. Quantification of IgG+, IgA+, and IgM+ ABCs by biaxial gating. * p<0.05, ** p<0.01, *** p<0.001 by by Mann-Whitney U test.


Disclosure: Y. Cao, None; S. Alves, Merck, 3; C. Sinnette, None; C. Speyer, None; G. Keras, None; Y. Qu, Merck, 3; J. Keegan, None; J. Lederer, None; D. Rao, Janssen, 5, Merck, 2, Pfizer, 5; K. Costenbader, Astra-Zeneca, 2, Glaxo Smith Kline, 2, Janssen Scientific Affairs, LLC, 2, Lupus Foundation of America, 2, Lupus Research Alliance, 2, Merck, 2.

To cite this abstract in AMA style:

Cao Y, Alves S, Sinnette C, Speyer C, Keras G, Qu Y, Keegan J, Lederer J, Rao D, Costenbader K. Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mass-cytometric-immunophenotyping-highlights-a-dysregulated-t-cell-b-cell-axis-in-patients-with-new-onset-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mass-cytometric-immunophenotyping-highlights-a-dysregulated-t-cell-b-cell-axis-in-patients-with-new-onset-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology